Table 2.
ATG4B inhibitors and their effect on cancer cell growth. N.D., not described.
| Compound | Chemical Scaffold | Screening Assay | Cell Type | Cancer Type | Reference |
|---|---|---|---|---|---|
| 7-keto-cholesterol | Keto-cholesterol | LC3–PLA2 | HASMC | N.D. | [116] |
| Aurin-tricarboxylic acid | Polyphenole | FRET (YFP–LC3–EmGFP) |
N.D. | N.D. | [100] |
| FMK9A | Methyl-ketone | TR–FRET | N.D. | N.D. | [117] |
| Hypericin | Anthra-quinone | FRET (YFP–LC3–EmGFP) |
N.D. | N.D. | [100] |
| LV-320 | Styryl-quinoline | In silico | SKBR3, MCF7, JIMT1, MDA-MB-231 | Breast Cancer | [106] |
| NSC185058 | Pyridine-carbothioamide | In silico | SAOS M83 |
Osteosarcoma Glioblastoma |
[98] [15] |
| NSC611216 | Benzo-indolone | Alphascreen | HT-29 | Colorectal cancer | [118] |
| S130 | Dibenzo-quinoline | In silico | HCT-116 | Colorectal cancer | [101] |
| Tioconazole | Dichlorphenylethyl-imidazole | In silico, GABARPL2–PLA | HCT-116 | Colorectal cancer | [93] |
| UAMC2526 | Benzo-tropolone | LC3–GST | HT-29 | Colorectal cancer | [115] |